1. bookTom 67 (2021): Zeszyt 2 (June 2021)
Informacje o czasopiśmie
Pierwsze wydanie
04 Apr 2014
Częstotliwość wydawania
4 razy w roku
Otwarty dostęp

Probiotics in the treatment of gastrointestinal diseases

Data publikacji: 17 Jul 2021
Tom & Zeszyt: Tom 67 (2021) - Zeszyt 2 (June 2021)
Zakres stron: 39 - 48
Otrzymano: 04 May 2021
Przyjęty: 08 Jun 2021
Informacje o czasopiśmie
Pierwsze wydanie
04 Apr 2014
Częstotliwość wydawania
4 razy w roku

1. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307:1915-1920. doi: https://dx.doi.org/10.1126/science.110481610.1126/science.110481615790844 Search in Google Scholar

2. Nash AK, Auchtung TA, Wong MC, et al. The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome 2017; 5:153. doi: https://dx.doi.org/10.1186/s40168-017-0373-410.1186/s40168-017-0373-4570218629178920 Search in Google Scholar

3. Scarpellini E, Ianiro G, Attili F, Bassanelli C, De Santis A, Gasbarrini A. The human gut micro-biota and virome: Potential therapeutic implications. Dig Liver Dis 2015; 47(12):1007-1012. doi: https://dx.doi.org/10.1016/j.dld.2015.07.00810.1016/j.dld.2015.07.008718561726257129 Search in Google Scholar

4. Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J 2017; 474(11): 1823–1836. doi: https://dx.doi.org/10.1042/BCJ2016051010.1042/BCJ20160510543352928512250 Search in Google Scholar

5. Guidelines for the evaluation of probiotics in food report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food. London Ontario, Canada April 30 and May 1, 2002. https://www.who.int/food-safety/fs_management/en/probiotic_guidelines.pdf Accessed: April 20, 2021. Search in Google Scholar

6. Gibson G. et al. Dietary prebiotics: current status and new definition. Food Sci Tech Bull Functional Foods 2010; 7:1-19.10.1616/1476-2137.15880 Search in Google Scholar

7. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489(7415):220-230. doi: https://dx.doi.org/10.1038/nature1155010.1038/nature11550357737222972295 Search in Google Scholar

8. El Aidy S, Derrien M, Aardema R, et al. Transient inflammatory-like state and microbial dysbiosis are pivotal in establishment of mucosal homeostasis during colonisation of germ-free mice. Benef Microbes 2014; 5:67-77. doi: https://dx.doi.org/10.3920/BM2013.001810.3920/BM2013.001824322881 Search in Google Scholar

9. Adak A, Khan MR. An insight into gut microbiota and its functionalities. Cell Mol Life Sci 2019; 76(3):473-493. doi: https://dx.doi.org/10.1007/s00018-018-2943-410.1007/s00018-018-2943-430317530 Search in Google Scholar

10. Savage DC. Microbial ecology of the gastrointestinal tract. Ann Rev Microbiol 1997; 31:107– 133. doi: https://dx.doi.org/10.1146/annurev.mi.31.100177.00054310.1146/annurev.mi.31.100177.000543334036 Search in Google Scholar

11. Lagier JC, Khelaifia S, Alou M, et al. Culture of previously uncultured members of the human gut microbiota by culturomics. Nat Microbiol 2016; 1:16203. doi: https://dx.doi.org/10.1038/nmicrobiol.2016.20310.1038/nmicrobiol.2016.20327819657 Search in Google Scholar

12. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307:1915-1920. doi: https://dx.doi.org/10.1126/science.110481610.1126/science.110481615790844 Search in Google Scholar

13. Markowiak P, Śliżewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients 2017; 9:1021. doi: https://dx.doi.org/10.3390/nu909102110.3390/nu9091021562278128914794 Search in Google Scholar

14. Hess JM, Jonnalagadda SS, Slavin JL. Dairy Foods: Current evidence of their effects on bone, cardiometabolic, cognitive, and digestive health. Compr Rev Food Sci Food Safe 2016; 15:251-268. doi: https://dx.doi.org/10.1111/1541-4337.1218310.1111/1541-4337.1218333371600 Search in Google Scholar

15. Bron PA, Kleerebezem M, Brummer RJ, et al. Can probiotics modulate human disease by impacting intestinal barrier function? Br J Nutr 2017; 117(1):93-107. doi: https://dx.doi.org/10.1017/S000711451600403710.1017/S0007114516004037529758528102115 Search in Google Scholar

16. Souvik T, John D, Ankita G. A review on probiotic dairy products and digestive health. J Pharmacogn Phytochem 2019; 8(3):368-372. Search in Google Scholar

17. Cleusix V, Lacroix C, Vollenweider S, Duboux M, Le Blay G. Inhibitory activity spectrum of reuterin produced by Lactobacillus reuteri against intestinal bacteria. BMC Microbiol 2007; 7:101. doi: https://dx.doi.org/10.1186/1471-2180-7-10110.1186/1471-2180-7-101222262917997816 Search in Google Scholar

18. Corr SC, Li Y, Riedel CU, O’Toole PW, Hill C, Gahan CG. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA 2007; 104(18):7617-7621. doi: https://dx.doi.org/10.1073/pnas.070044010410.1073/pnas.0700440104186347217456596 Search in Google Scholar

19. Rescigno M, Di Sabatino A. Dendritic cells in intestinal homeostasis and disease. J Clin Invest 2009; 119(9):2441-2450. doi: https://dx.doi.org/10.1172/JCI3913410.1172/JCI39134273593119729841 Search in Google Scholar

20. Corthésy B. Multi-faceted functions of secre-tory IgA at mucosal surfaces. Front Immunol 2013; 4:185. doi: https://dx.doi.org/10.3389/fimmu.2013.0018510.3389/fimmu.2013.00185370941223874333 Search in Google Scholar

21. Everard A, Geurts L, Caesar R, et al. Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status. Nat Commun 2014; 5:5648. doi: https://dx.doi.org/10.1038/ncomms664810.1038/ncomms6648426870525476696 Search in Google Scholar

22. Cash HL, Whitham CV, Behrendt CL, Hooper LV. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science 2006; 313:1126-1130. doi: https://dx.doi.org/10.1126/science.112711910.1126/science.1127119271666716931762 Search in Google Scholar

23. Marlicz W, Yung DE, Skonieczna-Żydecka K, et al. From clinical uncertainties to precision medicine: the emerging role of the gut barrier and microbiome in small bowel functional diseases. Expert Rev Gastroenterol Hepatol 2017; 11(10):961-978. doi: https://dx.doi.org/10.1080/17474124.2017.134366410.1080/17474124.2017.134366428618973 Search in Google Scholar

24. Bäckhed F, Fraser CM, Ringel Y, et al. Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe 2012; 12(5):611-622. doi: https://dx.doi.org/10.1016/j.chom.2012.10.01210.1016/j.chom.2012.10.01223159051 Search in Google Scholar

25. Wang L, Alammar N, Singh R, et al. Gut microbial dysbiosis in the irritable bowel syndrome: A systematic review and meta-analysis of case-control sudies. J Acad Nutr Diet 2020; 120(4):565-586. doi: https://dx.doi.org/10.1016/j.jand.2019.05.01510.1016/j.jand.2019.05.01531473156 Search in Google Scholar

26. Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol 2018; 11(1):1-10. doi: https://dx.doi.org/10.1007/s12328-017-0813-510.1007/s12328-017-0813-529285689 Search in Google Scholar

27. Syer SD, Blackler RW, Martin R, et al. NSAID enteropathy and bacteria: a complicated relationship. J Gastroenterol 2015; 50(4):387-393. doi: https://dx.doi.org/10.1007/s00535-014-1032-110.1007/s00535-014-1032-125572030 Search in Google Scholar

28. Layer P, Andresen V, Pehl C, et al. S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Verdauungsund Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM)1 [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. Z Gastroenterol 2011; 49(2):237-293. [in German] doi: https://dx.doi.org/10.1055/s-0029-124597610.1055/s-0029-124597621287438 Search in Google Scholar

29. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014; 109:S2-S26. doi: https://dx.doi.org/10.1038/ajg.2014.18710.1038/ajg.2014.18725091148 Search in Google Scholar

30. Zhang Y, Li L, Guo C, et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol 2016; 16:62. https://dx.doi.org/10.1186/s12876-016-0470-z10.1186/s12876-016-0470-z490725827296254 Search in Google Scholar

31. Korterink JJ, Ockeloen L, Benninga MA, Tabbers MM, Hilbink M, Deckers-Kocken JM. Probiotics for childhood functional gastrointestinal disorders: a systematic review and meta-analysis. Acta Paediatr 2014; 103(4):365-372. doi: https://dx.doi.org/10.1111/apa.1251310.1111/apa.1251324236577 Search in Google Scholar

32. Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2019; 4(4):CD004827. doi: https://dx.doi.org/10.1002/14651858.CD004827.pub510.1002/14651858.CD004827.pub5649079631039287 Search in Google Scholar

33. Szajewska H, Skórka A, Ruszczyński M, Gieruszczak-Białek D. Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children – updated analysis of randomised controlled trials. Aliment Pharmacol Ther 2013; 38(5):467-476. doi: https://dx.doi.org/10.1111/apt.1240310.1111/apt.1240323841880 Search in Google Scholar

34. Shan LS, Hou P, Wang ZJ, et al. Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with acute lower respiratory tract infections. Benef Microbes 2013; 4:329-334. doi: https://dx.doi.org/10.3920/BM2013.000810.3920/BM2013.000824311316 Search in Google Scholar

35. Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev 2010; 2010(11):CD003048. doi: https://dx.doi.org/10.1002/14651858.CD003048.pub310.1002/14651858.CD003048.pub3653269921069673 Search in Google Scholar

36. McFarland LV. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis 2007; 5:97-105. doi: https://dx.doi.org/10.1016/j.tmaid.2005.10.00310.1016/j.tmaid.2005.10.00317298915 Search in Google Scholar

37. Guerra PV, Lima LN, Souza TC, et al. Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World J Gastroenterol 2011; 17(34):3916-3921. doi: https://dx.doi.org/10.3748/wjg.v17.i34.391610.3748/wjg.v17.i34.3916319802122025880 Search in Google Scholar

38. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014; 109(10):1547-1562. doi: https://dx.doi.org/10.1038/ajg.2014.20210.1038/ajg.2014.20225070051 Search in Google Scholar

39. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012; 307:1959-1969. doi: https://dx.doi.org/10.1001/jama.2012.350710.1001/jama.2012.350722570464 Search in Google Scholar

40. Indrio F, Riezzo G, Raimondi F, et al. Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants. Eur J Clin Invest 2011; 41:417-422. doi: https://dx.doi.org/10.1111/j.1365-2362.2010.02425.x10.1111/j.1365-2362.2010.02425.x21114493 Search in Google Scholar

41. Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology 2006; 130(2 Suppl. 1):S78-S90. doi: https://dx.doi.org/10.1053/j.gastro.2005.11.04610.1053/j.gastro.2005.11.04616473077 Search in Google Scholar

42. Cheng J, Ouwehand AC. Gastroesophageal re-flux disease and probiotics: A systematic review. Nutrients 2020; 12(1):132. doi: https://dx.doi.org/10.3390/nu1201013210.3390/nu12010132701977831906573 Search in Google Scholar

43. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009; 29:938-946. doi: https://dx.doi.org/10.1111/j.1365-2036.2009.03960.x10.1111/j.1365-2036.2009.03960.x19220208 Search in Google Scholar

44. Hirayama F, Takagi S, Kusuhara H, Iwao E, Yokoyama Y, Ikeda Y. Induction of gastric ulcer and intestinal metaplasia in Mongolian gerbils infected with Helicobacter pylori. J Gastroenterol 1996; 31(5):755-757. doi: https://dx.doi.org/10.1007/BF0234763110.1007/BF023476318887049 Search in Google Scholar

45. Wang GZ, Huang GP, Yin GL, Zhou G, Guo CJ, et al. Aspirin can elicit the recurrence of gastric ulcer induced with acetic acid in rats. Cell Physiol Biochem 2007; 20(1-4):205-212. doi: https://dx.doi.org/10.1159/00010416710.1159/00010416717595529 Search in Google Scholar

46. Elliott SN, Buret A, McKnight W, Miller MJ, Wallace JL. Bacteria rapidly colonize and modulate healing of gastric ulcers in rats. Am J Physiol Cell Physiol 1998; 275(3):G425-G432. doi: https://dx.doi.org/10.1152/ajpgi.1998.275.3.G42510.1152/ajpgi.1998.275.3.G4259724253 Search in Google Scholar

47. Khoder G, Al-Menhali AA, Al-Yassir F, Karam SM. Potential role of probiotics in the management of gastric ulcer. Exp Ther Med 2016; 12(1):3-17. doi: https://dx.doi.org/10.3892/etm.2016.329310.3892/etm.2016.3293490669927347010 Search in Google Scholar

48. Clark PA, Cotton LN, Martin JH. Selection of bifidobacteria for use as dietary adjuncts in cultured dairy foods. II. Tolerance to simulated pH of human stomachs. Cult Dairy Prod J 1993; 28(4):11-14. Search in Google Scholar

49. Lankaputhra W, Shah NP. Survival of Lactobacillus acidophilus and Bifidobacterium spp. in the presence of acid and bile salts. Cult Dairy Prod J 1995; 30:2-7. Search in Google Scholar

50. Asaka M, Kato M, Kudo M, Meguro T, Kimura T, Miyazaki T, Inoue K. The role of Helicobacter pylori in peptic ulcer disease. Gastroenterol Jpn 1993; 28 (Suppl. 5):163-167. doi: https://dx.doi.org/10.1007/BF0298922810.1007/BF029892288359625 Search in Google Scholar

51. Zheng X, Lyu L, Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig 2013; 105(8):445-453. doi: https://dx.doi.org/10.4321/s1130-0108201300080000210.4321/S1130-01082013000800002 Search in Google Scholar

52. Lu C, Sang J, He H, Wan X, Lin Y, Li L et al. Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis. Sci Rep 2016; 6:23522. doi: https://dx.doi.org/10.1038/srep2352210.1038/srep23522480073326997149 Search in Google Scholar

53. Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology 2017; 152(2):327-339.e4. doi: https://dx.doi.org/10.1053/j.gastro.2016.10.01210.1053/j.gastro.2016.10.012551175627769810 Search in Google Scholar

54. Khanna S, Raffals LE. The microbiome in Crohn’s disease: Role in pathogenesis and role of microbiome replacement therapies. Gastroenterol Clin North Am 2017; 46(3):481-492. doi: https://dx.doi.org/10.1016/j.gtc.2017.05.00410.1016/j.gtc.2017.05.00428838410 Search in Google Scholar

55. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014; 146(6):1489-1499. doi: https://dx.doi.org/10.1053/j.gastro.2014.02.00910.1053/j.gastro.2014.02.009403413224560869 Search in Google Scholar

56. Colombel JF. Decade in review-IBD: IBD-genes, bacteria and new therapeutic strategies. Nat Rev Gastroenterol Hepatol 2014; 11(11):652-654. doi: https://dx.doi.org/10.1038/nrgastro.2014.17010.1038/nrgastro.2014.17025311475 Search in Google Scholar

57. Dong J, Teng G, Wei T, Gao W, Wang H. Methodological quality assessment of meta-analyses and systematic reviews of probiotics in inflammatory bowel disease and pouchitis. PloS one 2016; 11(12):e0168785. doi: https://dx.doi.org/10.1371/journal.pone.016878510.1371/journal.pone.0168785517908728005973 Search in Google Scholar

58. Limketkai BN, Akobeng AK, Gordon M, Adepoju AA. Probiotics for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2020; 7(7):CD006634. doi: https://dx.doi.org/10.1002/14651858.CD006634.pub310.1002/14651858.CD006634.pub3738933932678465 Search in Google Scholar

59. Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis 2014; 20(1):21-35. doi: https://dx.doi.org/10.1097/01.MIB.0000437495.30052.be10.1097/01.MIB.0000437495.30052.be24280877 Search in Google Scholar

60. Naidoo K, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2011; 12:CD007443. doi: https://dx.doi.org/10.1002/14651858.CD007443.pub210.1002/14651858.CD007443.pub222161412 Search in Google Scholar

61. Surawicz CM, McFarland LV. Pseudomembranous colitis: causes and cures. Digestion 1999; 60(2):91-100. doi: https://dx.doi.org/10.1159/00000763310.1159/00000763310095149 Search in Google Scholar

62. Dinleyici M, Vandenplas Y. Clostridium difficile colitis prevention and treatment. Adv Exp Med Biol 2019; 1125:139-146. doi: https://dx.doi.org/10.1007/5584_2018_32210.1007/5584_2018_32230689174 Search in Google Scholar

63. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108(4):500-508. doi: https://dx.doi.org/10.1038/ajg.2013.5910.1038/ajg.2013.5923511459 Search in Google Scholar

64. Stallmach A, Steube A, Grunert P, Hartmann M, Biehl LM, Vehreschild M. Fecal microbiota transfer. Dtsch Arztebl Int 2020; 117(3):31-38. doi: https://dx.doi.org/10.3238/arztebl.2020.003110.3238/arztebl.2020.0031702657032031511 Search in Google Scholar

65. Xu J, Ma R, Chen LF, Zhao LJ, Chen K, Zhang RB. Effects of probiotic therapy on hepatic encephalopathy in patients with liver cirrhosis: an updated meta-analysis of six randomized controlled trials. HBPD Int 2014; 13(4):354-360. doi: https://dx.doi.org/10.1016/s1499-3872(14)60280-010.1016/S1499-3872(14)60280-0 Search in Google Scholar

66. Cao Q, Yu CB, Yang SG, Cao HC, Chen P, Deng M, Li LJ. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis. HBPD Int 2018: 17(1):9-16. doi: https://dx.doi.org/10.1016/j.hbpd.2018.01.00510.1016/j.hbpd.2018.01.005 Search in Google Scholar

67. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011; 15(9):1090-1095. Search in Google Scholar

68. Buss C, Valle-Tovo C, Miozzo S, Alves de Mattos A. Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients. Ann Hepatol 2014; 13(5):482-488.10.1016/S1665-2681(19)31246-3 Search in Google Scholar

69. Oak SJ, Jha R. The effects of probiotics in lactose intolerance: A systematic review. Crit Rev Food Sci Nutr 2019; 59(11):1675-1683. doi: https://dx.doi.org/10.1080/10408398.2018.142597710.1080/10408398.2018.142597729425071 Search in Google Scholar

Polecane artykuły z Trend MD

Zaplanuj zdalną konferencję ze Sciendo